COPD and Spiriva

Last updated: N/A
Sponsor: N/A
Overall Status: Active - Recruiting

Phase

4

Condition

Copd (Chronic Obstructive Pulmonary Disease)

Chronic Obstructive Lung Disease

Treatment

N/A

Clinical Study ID

TX203437
  • Ages 40-100
  • All Genders

Study Summary

The purpose of this study is to compare a FDA approved single therapy inhaler that combines 3 COPD medications to Spiriva for patient convenience.

This study is about 3 months long and will consist of 6 office visits. All visits are conducted locally in Salt Lake City, Utah.

Eligibility Criteria

Inclusion

  • Be at least 40 years old.
  • Be diagnosed with COPD.
  • Be taking Spiriva consistently for 3 months.

Study Design

Study Start date:
Estimated Completion Date:

Study Description

Receive $125 per completed visit, starting after your 2nd visit. Study medications provided. No cost to participate. No insurance needed. No change in your doctor. Completely voluntary, no obligation to continue.